@article{wpf-surmount-5-weight-72w-v1.4.0,
  title = {SURMOUNT-5 (phase 3b, open-label): Tirzepatide vs semaglutide},
  doi = {10.1056/NEJMoa2416394},
  pmid = {40353578},
  note = {World Peptide Foundation WPF Flagship Weight Management, version 1.4.0, result surmount-5-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w},
  url = {https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w}
}

@article{wpf-step-1-weight-68w-v1.4.0,
  title = {STEP 1 (double-blind): Semaglutide 2.4 mg vs placebo, plus lifestyle intervention},
  doi = {10.1056/NEJMoa2032183},
  pmid = {33567185},
  note = {World Peptide Foundation WPF Flagship Weight Management, version 1.4.0, result step-1-weight-68w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=step-1-weight-68w},
  url = {https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w}
}

@article{wpf-surmount-1-weight-72w-v1.4.0,
  title = {SURMOUNT-1 (phase 3, double-blind): Tirzepatide 5, 10 or 15 mg vs placebo},
  doi = {10.1056/NEJMoa2206038},
  pmid = {35658024},
  note = {World Peptide Foundation WPF Flagship Weight Management, version 1.4.0, result surmount-1-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w},
  url = {https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w}
}

@article{wpf-retatrutide-phase2-weight-48w-v1.4.0,
  title = {Retatrutide phase 2 (double-blind): Retatrutide 1, 4, 8 or 12 mg vs placebo},
  doi = {10.1056/NEJMoa2301972},
  pmid = {37366315},
  note = {World Peptide Foundation WPF Flagship Weight Management, version 1.4.0, result retatrutide-phase2-weight-48w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=retatrutide-phase2-weight-48w},
  url = {https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w}
}

@article{wpf-jama-intern-med-2024-realworld-v1.4.0,
  title = {Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial: Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label)},
  doi = {10.1001/jamainternmed.2024.2525},
  pmid = {38976257},
  note = {World Peptide Foundation WPF Flagship Weight Management, version 1.4.0, result jama-intern-med-2024-realworld. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=jama-intern-med-2024-realworld},
  url = {https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld}
}
